ArticleEngineering in life sciences2017
Cell-penetrating peptide-labelled smart polymers for enhanced gene delivery.
Article in Engineering in life sciences, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Exploring delivery systems for targeted nanotechnology-based gene therapy in the inner ear.Therapeutic delivery · 2024Review
- Gene delivery by peptide-assisted transport.Current opinion in biomedical engineering · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Highly efficient gene delivery vehicles are pursued to progress gene therapy. In this study, we developed the cell-penetrating peptide-labelled and degradable gene carriers for efficient external gene transfection. The cationic carriers were prepared by coupling low-molecular-weight polyethylenimine (PEI800) with 4'4-dithiodibutyric acid (DA), and HIV-1 Trans-Activator of Transcription (TAT) was conjugated to the carriers as a penetrating peptide. The resulted PEI-DA-TAT was able to condense plasmid DNA (pDNA) into a complex with a hydrodynamic size of around 150 nm under a neutral condition. PEI-DA-TAT showed negligible cytotoxicity to both Hela and HEK 293 cells with the cell viability of more than 80% beyond the carrier concentration of 50 μg/mL. This new carrier displayed better performance in regard to DNA transfection efficiency in comparison with the carriers of non-TAT labelled PEI-DA, commercial PEI25K and low-molecular-weight PEI (PEI800). The transfection efficiency of PEI-DA-TAT was increased by 8% compared with PEI-DA and PEI25K. The experimental findings suggested that the developed PEI-DA-TAT is a promising carrier for efficient DNA delivery with low cytotoxicity for gene therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.